exhibit_99-1.htm

EXHIBIT 99.1

June 2015

Disclaimer

To the extent that statements contained in this presentation are not descriptions of historical facts regarding Foamix, they are forward-looking
statements reflecting management’s current beliefs and expectations. Forward-looking statements are subject to known and unknown risks,
uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be
materially different from those anticipated by such statements. In some cases, you can identify forward-looking statements by terminology such
as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “intends,” or “continue,” or the
negative of these terms or other comparable terminology. Forward-looking statements contained in this presentation include, but are not
limited to, (i) statements regarding the timing of anticipated clinical trials for our product candidates; (ii) the timing of receipt of clinical data for
our product candidates; (iii) our expectations regarding the potential safety, efficacy, or clinical utility of our product candidates; (iv) the size of
patient populations targeted by our product candidates and market adoption of our product candidates by physicians and patients; (v) the
timing or likelihood of regulatory filings and approvals; and (vi) our revenues under our agreements with our licensees, including Bayer, Actavis
and Merz.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, various factors may cause differences
between our expectations and actual results, including, but not limited to, unexpected safety or efficacy data, unexpected side effects observed
during preclinical studies or in clinical trials, lower than expected enrollment rates in clinical trials, changes in expected or existing competition,
changes in the regulatory environment for our product candidates and our need for future capital, the inability to protect our intellectual
property, and the risk that we become a party to unexpected litigation or other disputes. You should read the documents filed by Foamix with
the SEC, including our prospectuses, the Risk Factors set forth therein and the documents filed as exhibits to our registration statements, of
which the prospectuses are a part, completely and with the understanding that our actual future results may be materially different from what
we expect. You may obtain those documents by visiting EDGAR on the SEC website at www.sec.gov. Except as required by law, we assume no
obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those
anticipated in the forward-looking statements, even if new information becomes available in the future.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be
construed as an endorsement of the foam technology or product candidates of Foamix or this offering.

This document will not be left behind after this presentation and by accepting this document and attending the presentation you agree to be
bound by the foregoing limitations.

Highlights

Including Bayer, Actavis and Merz

Collaborations with leading pharma companies

Proprietary foam-based technology platform

Worldwide: over 110 granted patents; US: 39 granted patents

Innovative technology & extensive IP

Minocycline Foam

•FMX101 for moderate-to-severe Acne

•FMX103 for Rosacea

•FMX102 for Impetigo

Doxycycline Foam

•FDX104 for Chemotherapy-Induced Rash

Portfolio of clinical stage topical foam product candidates

Rehovot Israel & Bridgewater NJ

Strong dermatology track record

Integrated multinational management team

Financial Milestones

• IPO, September 2014

◦ Net proceeds: US 42.3 million

◦ Pricing: $6.0 per share

• Cash Position - Q1 2015

◦ As of March 31, 2015: $48.4 million

• Follow-on offering, April 2015

◦ Gross proceeds: US$ 69.0 million

◦ Net proceeds: ~ US$ 64.2 million (net of commissions and expenses)

◦ Pricing: $9.30 per share

Experienced Management Team

Name	Experience	Headquarters
Dov Tamarkin, PhD CEO & Director	• Led multiple product developments in dermatology • Led R&D operations in Israel, EU and US	Israel
Meir Eini Chairman & CIO	• Founder of multiple healthcare ventures	Israel
David Domzalski President, US	• Acted as head of commercial at Warner Chilcott and LEO • Led commercial launch of Doryx® and Taclonex®	US
Ilan Hadar CFO	• Held former finance roles at Israeli subsidiary of Pfizer, HP and BAE Systems	Israel
David Schuz EVP, IP	• Led IP operations at BTG Israel and Savient	Israel
Mitchell Shirvan, PhD SVP, R&D	• Former head of R&D, CNS division at Teva • Former CEO of MacroCure	Israel
Alvin Howard VP, U.S. Regulatory Affairs	• Acted as head of regulatory affairs at Warner Chilcott • Led approvals of 14 NDA and sNDAs	US
Herman Ellman, MD VP, U.S. Clinical Development	• Acted as head of clinical development at Warner Chilcott	US

Portman
Pharmaceuticals

Clilco

Flexiprobe

Differentiated Foam Technology with
Multiple Platforms

• Patented: over 110 granted patents worldwide(1)

◦ 39 granted US Patents(1)

• Capability to formulate multiple drugs

• Suitable for a variety of target sites

• Preferred dermatological alternative to oral delivery

Cream Foams

(Emulsion or Emollient)

Ointment Foams

(Petrolatum-based)

Waterless Hydrophilic

Foams (Enhanced penetration)

Oil Foams

Hydroethanolic Foams

Saccharide Foams

(For wounds and burns)

Potent Solvent Foams

(High solubility and delivery)

Suspension Foams

(Concentrated suspensions)

Nano-Emulsion Foams
(Enhanced penetration)

(1) As of March 31, 2015.

Foamix Foams vs. Hydroethanolic Foams

• Hydroethanolic foams are
unstable when heated

◦ Most foams contain alcohol and
readily collapse upon exposure to
skin temperature, hindering
usability

• Foamix foams are thermally
stable

◦ Does not readily collapse upon
exposure to skin temperature,
allowing easier application and
spreading

Foamix

Foam

Hydroethanolic

Foam

Collaborations with Third Parties

• Development and licensing agreements with pharmaceutical companies

• Each license agreement is product specific (Licensee’s drug)

• Licensed products are currently in preclinical, Phase II, Phase III and pre-approval stages

• We retain the rights to develop products for the same indications using our foam
technology in conjunction with other drugs

• We own the intellectual property for the drug delivery platform

• Upfront payments, contingent payments and royalties on sales of products that are
commercialized

• ~$18 million revenue received as of December 31, 2014

Pipeline of Late-Stage Product Candidates

• Pipeline also includes early-stage stable foam formulations with various drugs for the
treatment of common dermatological indications (e.g., anti-bacterials, anti-fungals and
corticosteroids)

Product Candidate	Phase I	Phase II	Phase III	Regulatory Pathway / Target Milestone
Minocycline Foam Candidates
FMX101 for Acne				• 505(b)(2) / Commence Phase III - early 2016 • Phase III data expected 2017 • NDA filing 2017
FMX102 for Impetigo				• 505(b)(2) / Commence Phase III pending FDA discussions
FMX103 for Rosacea				• 505(b)(2) / Commence Phase II in 2015 • Phase II data 2016
Doxycycline Foam Candidate
FDX104 for Chemotherapy- Induced Rash				• Phase II underway • Phase II data expected 2015

FMX101

Topical Minocycline Foam
For Moderate-to-Severe Acne

FMX101: For Moderate-to-Severe Acne

• We successfully stabilized minocycline in a novel topical foam formulation

• Foam delivers minocycline directly to the pilosebaceous unit

• Ex-vivo study showed: Minocycline penetrates into the
pilosebaceous unit

Targeted Delivery to the Pilosebaceous Unit(2)

Sebum
composition

Sebum composition

FMX101 Vehicle

FMX101’s Unique Vehicle Dissolves Sebum Composition(1)

(1) Laboratory study, data on file - Foamix Pharmaceuticals Ltd. (2) Study performed at Charité Universitätsmedizin Berlin.

FMX101: Phase II Clinical Trial - Study Design

• Self-apply to the same region, once daily, in the evening for 12 weeks

• At least 20 inflammatory and 25 non-inflammatory lesions

• Endpoints

◦ Change in acne lesions

◦ Investigator’s Global Assessment (IGA)

◦ Safety and tolerability

12-week, randomized, double-blind, dose range-finding study in
subjects with moderate-to-severe acne

Week 12

(End of treatment)

Week 16
(Follow-up)

Week 3

Week 6

Week 9

Randomized (1:1:1), double-blind

N=150

• Minocycline foam 1%(1)

• Minocycline foam 4%(1)

• Foam vehicle(1)

(1) Data on file - Foamix Pharmaceuticals Ltd. Study FX2010-03 CSR.

FMX101: Phase II Clinical Trial Results

% Reduction of Non-Inflammatory Lesions

% Reduction of Inflammatory Lesions

* p ≤ 0.05

* * p ≤ 0.01

Foam Vehicle

Minocycline 1%

Minocycline 4%

Dose-dependent reduction of inflammatory and non-inflammatory acne

(1)

(1) Represents end of treatment.

FMX101: Comparison
Oral minocycline and topical anti-acne drugs for moderate-
to-severe acne

Literature Comparison (12 Weeks of Treatment)

(1) Source: Prescription Instruction leaflets of Solodyn, Epiduo and Aczone (average of studies reported for each drug), (2) Head-to-head trials with
FMX101 were not conducted.

	4% Minocycline Foam	Solodyn(1)(2) (oral minocycline)	Epiduo(1)(2) (Adapalene + BPO Gel)	Aczone(1)(2) (Dapsone Cream)
% Reduction of inflammatory lesions	72%	44%	47%	47%
% Reduction of non- inflammatory lesions	73%	No effect	50%	31%

FMX101: Effects on Moderate-to-Severe
Acne Patients

FMX101 Phase II Clinical Trial: Patient with moderate-to-severe acne
who responded positively to our treatment (Minocycline Foam 4%)

FMX101: Effects on Moderate-to-Severe
Acne Patients (cont’d)

FMX101 Phase II Clinical Trial: Patients with moderate-to-severe acne
who responded positively to our treatment (Minocycline Foam 4%)

12 Weeks

Baseline

FMX101 - Commercial Overview

Moderate-to-Severe Acne: Unmet Medical Need
Moderate-to-severe acne prevalence ~10 million people in the US

Mild Acne

Less than 30 lesions

<15 Inflammatory lesions

Moderate Acne
<50 Inflammatory lesions

Severe

Acne

>50 Inflammatory lesions

Topical

Target market for
minocycline foam
(FMX101)

Oral antibiotics

Total US acne prevalence = 40-50 million people per year

Source: Symphony Health Analytics DCL (Dynamic Claims Lifecycle).

Form	US Dollars
Topical	$1.3 billion
Oral	$1.7 billion
Total	$3.0 billion

A Competitive Landscape with No Dominant Leader
Top brands oral and topical formulations (LTM January 2015)

Source: Symphony Health Analytics DCL (Dynamic Claims Lifecycle).

(1) Indicated for the treatment of Rosacea, (2) The charts show the respective market shares of the oral branded prescription acne drug market and
the topical branded prescription acne drug market according to the total number of prescriptions.

	Top Oral Brands	US Dollars
1	ORACEA (1)	$399,553,613
2	SOLODYN	378,680,981
3	DORYX	236,947,892
4	MONODOX	180,363,148
5	ACTICLATE	103,068,443

	Top Topical Brands	US Dollars
1	EPIDUO	$392,925,581
2	ACZONE	357,780,787
3	FINACEA (1)	149,158,927
4	ACANYA	139,396,592
5	ZIANA	124,444,412

(1
)

A Pro-Commercial Reimbursement Environment
Payer mix: branded acne drugs (all payer types / LTM January 2015)

Source: Symphony Health Analytics DCL (Dynamic Claims Lifecycle).

(1) Assistance Programs include aid for “medically indigent” patients (those who are without insurance, have low income or are ineligible for public
programs) which can be privately or State funded and coupon programs that have been identified and profiled.

Commercial Payers and Cash account for 71% of total
reimbursement within the Oral Branded Market.

Oral

Commercial Payers and Cash account for 78% of total
reimbursement within the Topical Branded Market.

Topical

(1)

Prescription (Rx) Volume Driven by Small
Prescriber Base
Attractive and efficient for commercialization

Source: Symphony Health Analytics DCL (Dynamic Claims Lifecycle). Data from April 2012 - March 2014.

Total Active Derms

(13,971)

Rx Volume

(80%)

Rx Volume

(100%)

• ~33% of dermatologists
generate ~80% of Rx
volume

• Foamix intends to utilize
a small, dedicated sales
force deployment to
optimize coverage

• 50-75 reps

Target Universe

Derms

(4,538)

FMX103

Topical Minocycline Foam
For Rosacea

FMX103: Rosacea

• FMX103 is a minocycline foam in development for the treatment of
rosacea

• Rosacea lesions and inflammatory acne lesions have a number of
dermatological similarities

• Approximately 16 million people are afflicted

◦ ~$1.2 Billion market(1)

  ◦ Current treatment options include topicals such as azaleic acid
       (Finacea®) and metronidazole (Metrogel®), as well as oral
       minocycline or oral doxycycline (Oracea®)

• Commence Phase II trial (2015)

(1) Symphony Health Analytics DCL (Dynamic Claims Lifecycle).

Planned: 210 subjects

12 weeks’ treatment duration

Efficacy evaluation
and safety
assessments
performed at weeks
1, 2, 4, 6, 8, 10, and
12

FMX103

(high dose)

~70 subjects

FMX103

(low dose)

~70 subjects

Foam vehicle

(placebo)

~70 subjects

Randomized (1:1:1)

Randomized, Multicenter, Double-Blind, Vehicle-Controlled Study

Facial Rosacea

Safety Assessments

• Standard safety measures

• Other rosacea signs and symptoms

Primary Efficacy Assessments

• Inflammatory lesion count

• IGA scores

Clinical Study Protocol - Foamix Ltd. Study FX2014-06.

FMX103: Phase II Study Design

(1) The chart below shows the approximate market shares of the branded prescription rosacea drug market according to total number of
prescriptions.

Total Market: ~$1.2 billion


1	ORACEA (oral doxycycline)	$297,941,611
2	METRONIDAZOLE	$270,704,800
3	FINACEA	$125,135,634
4	MIRVASO	$49,014,674
5	DOXYCYCLINE	$37,816,825

FMX102

Topical Minocycline Foam
For Impetigo, Including MRSA

FMX102: Impetigo

• FMX102 is a low dose formulation of minocylcine foam in development for the treatment
of impetigo, including MRSA infections

• Impetigo is a highly contagious bacterial skin infection, primarily affecting preschool-aged
children

• US market size approximately $330 million

◦ Majority of market attributed to Bactroban and other mupirocin-based topical products

• Phase II trial completed in 2012

◦ Design: randomized, double-blind study, without a control group, of 32 pediatric
patients with at least 2 impetigo lesions (11 had MRSA infection)

◦ Treatment: 1% or 4% minocycline foam was applied topically twice-daily for 7 days,
with an additional follow-up at 14 days

◦ End Points: absence or improvement(1) of treated lesions and dried lesions without
crusts, with/without erythema

(1) Data on file - Foamix Pharmaceuticals Ltd. Study FX2010-01; draft CSR.

FMX102: Phase II Trial Results

• Current benchmark BACTROBAN® (mupirocin) achieves 71%-96% of clinical efficacy within
8-12 days of treatment

D. Foam: A unique delivery vehicle for topically applied formulations. In: Dayan N. Apply Topically: A Practical

81.3%

92.3%

100%

Day 3

Day 7 (end of treatment)

Day 14 (follow-up)

(1) 1% and 4% Minocycline were equally effective after Day 14 and substantially similar after Days 3 and 7. Data on file - Foamix Pharmaceuticals
Ltd. Study FX2010-01; draft CSR.

Efficacy

FMX102: Phase II Trial Results
Visible improvement / lesion clearance with treatment(1)

Baseline

Day 3

Day 7 (End of treatment)

Patient A

Patient B

Patient C

(1) Patients A, B and C received minocycline foam 1%.

FDX104

Topical Doxycycline Foam
For Treatment of Chemotherapy-Induced Rashes

FDX104: For Chemotherapy-Induced Rash

• Background

◦ Patients taking Erbitux (and other EGFRI drugs) are affected by
severe acne-like rashes

◦ Between 45% to 100% of EGFRI patients develop severe acne-
like rashes

◦ 32% discontinue therapy

◦ No approved treatments for chemotherapy-induced rashes

◦ Oral doxycycline and minocycline are used ‘off-label’

◦ Limitations

◦ Systemic side effects

◦ Potential drug-drug interaction with EGFRI drugs

• Product: Doxycycline Foam 4%

• Phase II trial commenced Q4, 2014

◦ Target Enrollment: 24 patients

◦ Expected top line results - 2015

Highlights

Including Bayer, Actavis and Merz

Collaborations with leading pharma companies

Proprietary foam-based technology platform

Worldwide: over 110 granted patents; US: 39 granted patents

Innovative technology & extensive IP

Minocycline Foam

•FMX101 for moderate-to-severe Acne

•FMX103 for Rosacea

•FMX102 for Impetigo

Doxycycline Foam

•FDX104 for Chemotherapy-Induced Rash

Portfolio of clinical stage topical foam product candidates

Rehovot Israel & Bridgewater NJ

Strong dermatology track record

Integrated multinational management team

May 2015